Absence of MPTP-Induced Neuronal Death in Mice Lacking the Dopamine Transporter

MPTP has been shown to induce parkinsonism both in human and in nonhuman primates. The precise mechanism of dopaminergic cell death induced following MPTP treatment is still subject to intense debate. MPP+, which is the oxidation product of MPTP, is actively transported into presynaptic dopaminergic nerve terminals through the plasma membrane dopamine transporter (DAT). In this study, we used mice lacking the DAT by homologous recombination and demonstrated that the MPTP-induced dopaminergic cell loss is dependent on the presence of the DAT. For this we have used tyrosine hydroxylase immunoreactivity (TH-IR) labeling of dopamine cells of the substantia nigra compacta in wild-type, heterozygote, and homozygote mice that were given either saline or MPTP treatments (two ip injections of 30 mg/kg, 10 h apart). Our results show a significant loss of TH-IR in wild type (34.4%), less loss in heterozygotes (22.5%), and no loss in homozygote animals. Thus dopamine cell loss is related to levels of the DAT. These results shed light on the degenerative process of dopamine neurons and suggest that individual differences in developing Parkinson's disease in human may be related to differences of uptake through the DAT of a yet unidentified neurotoxin.

[1]  E. Bézard,et al.  Kinetics of nigral degeneration in a chronic model of MPTP-treated mice , 1997, Neuroscience Letters.

[2]  G. Uhl,et al.  Parkinsonism‐inducing neurotoxin MPP+: Uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA , 1992, Annals of neurology.

[3]  D. D. Di Monte,et al.  Increased efflux rather than oxidation is the mechanism of glutathione depletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1987, Biochemical and biophysical research communications.

[4]  E. Bézard,et al.  Effects of Different Schedules of MPTP Administration on Dopaminergic Neurodegeneration in Mice , 1997, Experimental Neurology.

[5]  J. Langston,et al.  Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity? , 1985, Life sciences.

[6]  H. S. Neto,et al.  Ciliary neurotrophic factor stimulates in vivo myotube formation in mice , 1997, Neuroscience Letters.

[7]  D. Mash,et al.  Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons , 1994, Annals of neurology.

[8]  H. Przuntek,et al.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. , 1991, European journal of pharmacology.

[9]  G. Uhl,et al.  Dopamine transporter mRNA: dense expression in ventral midbrain neurons. , 1992, Brain research. Molecular brain research.

[10]  Z. Rossetti,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. , 1988, Biochemical pharmacology.

[11]  W. Schultz,et al.  Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism , 1985, Neuroscience Letters.

[12]  M. Caron,et al.  The dopamine transporter: A crucial component regulating dopamine transmission , 1997, Movement disorders : official journal of the Movement Disorder Society.

[13]  M. Bannon,et al.  Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Snyder,et al.  Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. , 1984, European journal of pharmacology.

[15]  S. Amara,et al.  Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. D. Di Monte,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. , 1986, Biochemical and biophysical research communications.

[17]  R. Edwards,et al.  Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. German,et al.  Midbrain dopaminergic neurons in the mouse: Computer‐assisted mapping , 1996, The Journal of comparative neurology.

[19]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[20]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Burke,et al.  Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[22]  P. Sonsalla,et al.  Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. , 1989, Molecular and chemical neuropathology.

[23]  M. Caron,et al.  The dopamine transporter. The cloned target site of parkinsonism-inducing toxins and of drugs of abuse. , 1996, Advances in neurology.

[24]  M. Caron,et al.  Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  G. Uhl,et al.  Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain. , 1993, Brain research. Molecular brain research.

[26]  A. Schapira,et al.  Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.

[27]  R. Mark Wightman,et al.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.

[28]  R. Gainetdinov,et al.  Dopamine Transporter Is Required for In Vivo MPTP Neurotoxicity: Evidence from Mice Lacking the Transporter , 1997, Journal of neurochemistry.

[29]  J. Cano,et al.  Nigral and Striatal Comparative Study of the Neurotoxic Action of 1‐Methyl‐4‐Phenylpyridinium Ion: Involvement of Dopamine Uptake System , 1996, Journal of neurochemistry.

[30]  E. Bézard,et al.  A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey , 1997, Brain Research.

[31]  S. Hersch,et al.  The dopamine transporter: immunochemical characterization and localization in brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  G. Uhl.  Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease , 1998, Annals of neurology.

[33]  D. German,et al.  The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[34]  P. McKenna,et al.  Co-expression of dopamine transporter mRNA and tyrosine hydroxylase mRNA in ventral mesencephalic neurones. , 1993, Brain research. Molecular brain research.

[35]  W. Wetsel,et al.  Anterior Pituitary Hypoplasia and Dwarfism in Mice Lacking the Dopamine Transporter , 1997, Neuron.

[36]  P. Sonsalla,et al.  The MPTP-treated mouse as a model of Parkinsonism: How good is it? , 1992, Neurochemistry International.

[37]  P. Sonsalla,et al.  The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. , 1986, European journal of pharmacology.